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1. Introduction
Melanoma is a cancer that develops in melanocytes, the pigment cells present in the skin. It
can be more serious than the other forms of skin cancer because it may spread to other parts
of the body (metastasize) and cause serious illness and death. For malignant melanomas
standard treatment options have remained remarkably static over the past 30 years [1,2]. At
present, the incidence of melanoma continues to increase despite public health initiatives that
have promoted protection against the sun. Thus, during the past ten years, the incidence and
annual mortality of melanoma has increased more rapidly than any other cancer and according
to the American Cancer Society estimate, there will have been approximately 76,250 new cases
of invasive melanoma diagnosed in 2012 in the United States, which resulted in approximately
9,180 deaths [3].
Unfortunately, the increase in incidence has not been paralleled by the development of new
therapeutic agents with a significant impact on survival. Although many patients with mela‐
noma localized to the skin are cured by surgical excision, increased time to diagnosis is asso‐
ciated with higher stage of disease, and those with regional lymphatic or metastatic disease
respond poorly to conventional radiation and chemotherapy with 5-year survival rates rang‐
ing from 10 to 50% [4]. Currently, limited therapeutic options exist for patients with metastatic
melanomas, and all standard combinations currently used in metastasis therapy have low
efficacy and poor response rates. For instance, the only approved chemotherapy for metastatic
melanoma, dacarbacine, has a response rate of about 10% and a median survival of 8-9 months.
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The other approved agent for advanced melanoma is high dose interleukin-2, which can induce
dramatic complete and durable responses [2]. However, only one patient in twenty derives
lasting benefit. These data indicate the needed for alternative therapies for this disease and
recent results indicated that combined therapies could became an attractive strategy to fight
melanoma [2].
Other example of the complications involved in melanoma chemotherapy is the limited effec‐
tiveness of antifolates. Although methotrexate (MTX), the most frequently used antifolate, is
an efficient drug for several types of cancer, it is not active against melanoma [5-7]. Undoubt‐
edly, unravelling the mechanisms of melanoma resistance to MTX could yield important in‐
formation on how to circumvent this resistance and could have important pharmacological
implications for the design of novel combined therapies. Thus, although an old drug, MTX
could become a valuable tool with which to improve melanoma therapy.
2. General mechanisms of resistance to classical antifolates
The antifolate methotrexate was rationally-designed nearly 70 years ago to potently block the
folate-dependent enzyme dihydrofolate reductase (DHFR). DHFR (5,6,7,8-tetrahydrofolate:
NADP+ oxidoreductase, EC 1.5.1.3) catalyses the reduction of 7,8-dihydrofolate (DHF) to
5,6,7,8-tetrahydrofolate (THF) in the presence of coenzyme NADPH as follows: DHF +
NADPH + H+ → THF + NADP+. This enzyme is necessary for maintaining intracellular pools
of THF and its derivatives which are essential cofactors in one-carbon metabolism. Coupled
with thymidylate synthase (TS) [8], it is directly involved in thymidylate (dTMP) production
through a de novo pathway. DHFR is therefore pivotal in providing purines and pyrimidine
precursors for the biosynthesis of DNA, RNA and amino acids. In addition, it is the target
enzyme [9] for antifolate drugs such as the antineoplastic drug MTX and the antibacterial drug
trimethoprim (TMP). The mechanisms of resistance to MTX have been extensively studied,
mainly in experimental tumours propagated in vitro and in vivo [5,10,11]; however, the specific
basis for the resistance of melanoma cells to MTX is unclear. During decades the mechanism
of resistance of melanoma to MTX was associated with general mechanisms of resistance de‐
tected in other epithelial cancer cell including reduced cellular uptake of this drug, high in‐
tracellular levels of DHFR and/or insufficient rate of MTX polyglutamylation, which
diminishes long-chain MTX polyglutamates from being preferentially retained intracellularly
[11]. However, recently, a melanoma-specific mechanism of resistance to cytotoxic drugs, in‐
cluding MTX, has been described [6,12,13].
Antifolate resistance in cancer cells is believed to be a multifactorial process in which dysre‐
gulation of apoptosis, insufficient rates of MTX polyglutamylation, and enhanced DNA repair
play important roles [11,14]. In melanoma, another classical mechanism of resistance to MTX,
the upregulation of endogenous dihydrofolate reductase (DHFR) activity, has been described
[5]; however, the contribution of this mechanism to the overall resistance of melanoma to MTX
as well as its possible impact on DNA damage response pathways in cells is unknown. ‘Thy‐
mineless’ death, which occurs upon the depletion of cellular dTTP pools, has been proposed
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as a mechanism by which antifolate drugs promote apoptosis in cancer cells [15,16]. Although
the mechanism of dTTP depletion-induced apoptosis is yet to be determined, Pardee’s group
recently postulated that dTTP controls E2F1, which regulates both DNA synthesis and apop‐
tosis. This hypothesis was based on the observation that MTX increased E2F1 levels in sensitive
cancer cells, resulting in an increase in the E2F1-mediated apoptotic cascade.
Eukaryotic cells have developed complex checkpoint pathways that monitor DNA for damage
or incomplete replication. Checkpoint pathways are amplified upon detection of aberrant
DNA structures and lead to a delay in cell cycle progression during which damage can be
repaired or replication be completed. Alternatively, in case of heavily damaged or seriously
deregulated cells, checkpoint activation can result in apoptosis. As such, checkpoint mecha‐
nisms are essential for the maintenance of genomic integrity [17]. When vertebrate cells expe‐
rience replication arrest or undergo DNA damage by UV irradiation, the ATR kinase [ataxia
telangiectasia mutated (ATM)- and Rad3-related kinase] phosphorylates and activates the
Chk1 protein kinase. Activated Chk1 inhibits Cdc25 phosphatases, which control inhibitory
phosphorylation sites on cyclin-dependent kinases, the latter being critical regulators of cell
cycle transitions [18,19]. Because the ability of cells to delay cell cycle progression and halt
DNA synthesis represents a defensive mechanism that spares potential toxicity [20], the acti‐
vation of Chk1 by MTX could constitute a key event in the resistance of melanoma to MTX.
In addition to these cellular mechanisms of resistance to MTX in melanoma, other mechanism
that includes liver transformation of the drug has also been reported. A paradoxical response
of malignant melanoma to MTX in vivo and in vitro has been described [21]. The authors ob‐
served that MTX showed consistent cytotoxicity for melanoma cells in vitro but was ineffective
at equivalent concentrations in vivo. MTX undergoes oxidation to its primary metabolite 7-
hydroxy-MTX (7-OH-MTX) in the liver by the enzyme aldehyde oxidase [11] and therefore,
this transformation has been proposed as a novel mechanism of resistance to explain this par‐
adox [11,21]. In contrast to the large body of literature available on the multiple modalities of
MTX resistance, very little is known regarding the ability of 7-OH-MTX to provoke antifolate-
resistance phenomena that may disrupt MTX activity. Recent studies seem to indicate that 7-
OH-MTX which exceeds by far MTX in the plasma of MTX-treated patients can provoke
distinct modalities of antifolate-resistance that severely compromise the efficacy of the parent
drug MTX [22].
3. Melanoma-specific mechanisms of resistance to MTX
3.1. The critical role of alpha-folate receptor in the resistance of melanoma to MTX
Experiments from our laboratory and others provide evidence that melanosomes contribute
to the refractory properties of melanoma cells by sequestering cytotoxic drugs and increasing
melanosome-mediated drug export [6,12,13]. Concretely, we have described that folate recep‐
tor α (FRα)-endocytotic transport of MTX facilitates drug melanosomal sequestration and cel‐
lular exportation in melanoma cells, which ensures reduced accumulation of MTX in
intracellular compartments [6]. An important observation in this study was that MTX was a
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cytostatic agent on melanoma cells. These cells were resistant to MTX-induced apoptosis but
responded to the drug by arresting their growth. A similar response was observed when the
murine B16/F10 melanoma cell line was grown in low folate. After 3 days in folate-deficient
medium the cells had restricted proliferative activity and also increased their metastatic po‐
tential [23]. Taking this into consideration, the results indicate that MTX might also induce
depletion of intracellular reduced folate coenzymes by reducing their transport though the
FRα and/or competing with them for the reduced folate carrier (RFC). Melanoma cells may be
highly sensitive to intracellular depletion of folate coenzymes, and in this situation may enter
into a “latent” state. This form of melanoma should indeed be highly resistant to MTX, since
antifolate drugs are more effective on fast-dividing cells, which require continuous DNA syn‐
thesis. Most likely, the high increases of DHFR expression in cells treated with MTX [5] would
represent an adaptation mechanism that allows cells to survive with low intracellular concen‐
trations of folate coenzymes. Increasing the recycling of folate molecules the cells would main‐
tain other cellular functions that are dependent on folate coenzymes, such as the synthesis of
purines, pyrimidines, amino acids and methylation reactions. The presence of this “latent”
form of melanoma should be critical for the resistance to MTX during in vivo therapies. Al‐
though MTX chemotherapy could initially halt the development of the tumor, after clearance
of the drug from the body the melanoma cells may reinitiate their progression, possibly with
an increased metastatic potential [23].
A defect in intracellular folate retention is another recognized mechanism of drug resist‐
ance  [5,10,11,21].  In  addition  to  a  decrease  in  antifolate  polyglutamylation,  melanoma
cells may also export cytotoxic drugs by melanosome sequestration [12]. The results pre‐
sented in this study indicated that drug exportation was an operative mechanism of re‐
sistance to  MTX in melanoma cells.  Although the mechanism by which cytotoxic  drugs
are sequestered into melanosomes remains unclear,  we demonstrated that  MTX-melano‐
some trapping may be a consequence of its FRα-endosomal transport [6]. To test the im‐
portance  of  this  process  on  the  resistance  of  melanoma  to  antifolates,  we  silenced  the
expression of the melanosomal structural protein gp100/Pmel17, which is known to play
a critical role in melanosome biogenesis [24]. Recently, Xie and collaborators [13] provid‐
ed the first direct evidence that disruption of the process of normal melanosome biogen‐
esis,  by  mutation  of  gp100/Pmel17,  increased  sensitivity  to  cisplatin.  We  also  observed
that effective silencing of gp100/Pmel17 significantly increased the sensitivity of melano‐
ma cells  to MTX, favouring MTX-induced apoptosis.  This  observation strongly supports
the hypothesis which indicates that melanosome biogenesis is a specialization of the en‐
docytic  pathway [25,26];  however,  the  exact  mechanism by  which  MTX induces  abnor‐
mal  trafficking  of  early  endosomes  in  melanoma  cells,  favoring  the  exportation  of
melanosomes,  is  still  unclear.  Whether MTX blocks the formation of  carrier  vesicles  op‐
erating between early and late endosomes, inhibits the delivery of endocytosed material
from endosomes to lysosomes,  promoting,  thus,  the generation of  exosomes [26]  and/or
induces  a  failure  of  lysosomal  acidification,  which  is  essential  for  normal  endocytosis
[27], remains to be determined.
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Figure 1. A) Possible mechanisms for transport and trafficking of folates in melanoma cells. (B) Mechanisms to explain
the MTX-induced depletion of DHF in melanoma cells. (C) Folate deficiency induces DHF depletion and enhances the
transactivational potential of E2F1. (D) Excess of dTTP inhibits E2F1-mediated apoptosis and activates Chk1 in melano‐
ma cells. High levels of DHFR and TS could reactivate de novo dTMP biosynthesis impeding depletion of dTTP. Excess of
dTTP would prevent apoptosis by several mechanisms. First, dTTP is an allosteric inhibitor of ribonucleotide reductase
(RR), the enzyme which reduces cytidine diphosphate (CDP) and uridine diphosphate to dCDP and dUDP.
To explore the relationship between MTX exportation and melanosome trafficking, we studied
the possible interaction of MTX with melanin [6]. Such interaction was confirmed by incubating
this drug with synthetic 3,4-dihydroxyphenylalanine (DOPA)-melanin. Importantly, folic acid
and 5-methyl-THF (5-MTHF), the natural source of cellular folates, did not appear to interact
with synthetic DOPA-melanin. A comparison of the interaction of several folates (folic acid
and 5-MTHF) and antifolates (MTX and aminopterin) with synthetic DOPA-melanin indicated
that the double amino group of the pterin ring is an important molecular requirement for the
drug-melanin interaction. Therefore, the physiological importance of the high affinity of mel‐
anin for antifolates, such as MTX and aminopterin, for drug melanosomal sequestration is also
another important issue that remains to be addressed. Endocytic transport of molecules in‐
volves several processes, including the fusion of early and late endosomes and the dissociation
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of receptor-ligand complexes through the acidic pH of preformed vesicles [28]. After melano‐
some biogenesis from MTX-loaded endosomes, dissociated MTX could be trapped in the mel‐
anosomes by its interaction with melanins. In contrast, folate substrates would not be
sequestered in melanosomes due to their low affinities for melanin; facilitated by the acidic
pH of this organelle, uncharged reduced folates would leave the melanosome by passive dif‐
fusion and reach the cytosol, where they would become available for cellular functions. There‐
fore, elucidation of the molecular basis for the (anti)folate interaction with melanins could have
important therapeutic implications, and this study might be used as a guide for the synthesis
of new antifolates or for using existing antifolates in ways that escape melanin trapping.
3.2. MTX disrupts folate trafficking in melanoma cells
Although MTX is exported within a few hours in contact with cells, in this short time, MTX is
capable of inducing important changes in folate metabolism by depleting dihydrofolate (DHF)
early on and by inducing the expression of folate-dependent enzymes later on [7]. The in‐
creased expression of DHFR is a common occurrence in melanoma and other cancer cells in
response to MTX treatment; however, the observed depletion of DHF was completely unex‐
pected. The pathways that comprise folate-mediated one-carbon metabolism have been sug‐
gested to function in a metabolic network that interconnects the three biosynthetic pathways,
namely de novo purine biosynthesis, de novo dTMP biosynthesis, and homocysteine remethy‐
lation. Recent studies provide direct evidence for cell cycle–dependent nuclear dTMP biosyn‐
thesis in the nucleus [29]. However, there are many unanswered questions regarding the role
and regulation of nuclear de novo dTMP biosynthesis. Nothing is known about the transport,
processing, and accumulation of folates into the nucleus, the one-carbon forms of folate present
in the nucleus, and the relationship between cell cycle dependency of de novo dTMP biosyn‐
thesis and cell cycle-dependent accumulation of nuclear folate [29]. Although there is no data
of how the homocysteine remethylation cycle is compartmentalized, the observation that MTX
affected both DHF synthesis and E2F1 methylation (see below) seem to indicate that both the
de novo dTMP biosynthesis and the homocysteine remethylation cycles might operate simul‐
taneously in the nucleus.
Using HeLa and MCF-7 cells, Stover and coworkers observed that cytoplasmic serine hydrox‐
ymethyltransferase (SMTH), TS, and DHFR are all translocated into the nucleus during S and
G2/M phases following their modification by the small ubiquitin-like modifier (SUMO) [30,31].
This finding indicated that the folate cycle may be compartmentalized and that dTMP and
DHF synthesis may occur in the nucleus during DNA synthesis. In a recent study, Wollack et
al. [32] characterized 5-MTHF uptake and metabolism by primary rat choroid plexus epithelial
cells in vitro. They distinguish two different processes for 5-MTHF transport, one that was
FRα dependent and the other that was independent of this receptor and mediated by the proton
couple folate transporter or reduced folate carrier (RFC). This investigation revealed that cel‐
lular metabolism of 5-MTHF depends on the route of folate entry into the cell. Thus, 5-MTHF
taken up via a non-FRα–mediated process was rapidly metabolized to folylpolyglutamates,
whereas 5-MTHF that accumulates via FRα remained non-metabolized and associated to en‐
docytic compartments. The observation that MTX induces the overall depletion of FRα in
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melanoma cells [6] would suggest that MTX might also induce depletion of reduced folate
coenzymes associated to endocytic compartments (Figure 1A and 1B). Therefore, a possible
explanation for the depletion of DHF during MTX exposure could be that this drug diminishes
the required supply of folates to the nucleus for the maintenance of both dTMP and DHF
synthesis; however, how melanoma cells can control endocytic pathways to supply their own
nucleus with folates is unknown. Recent studies have indicated that some endocytic proteins
are also involved in direct signaling pathways from membranes to the nucleus, and mecha‐
nisms for the nuclear translocation of intact or fragmented endosome-localized proteins have
been identified [33]. Another possibility is the existence of a late endosome-lysosome transport
mechanism for folate [34]. The proximity of lysosomes to the nucleus suggests that folates
could be released into the perinuclear region of the cytoplasm, perhaps facilitating their nuclear
entry during cell division following the disassembly of the nuclear membrane [29].
Although the uptake of 5-MTHF into mammalian cells is mainly mediated by the RFC, the
expression of FRα in several epithelial tissues and especially its overexpression in cancerous
cells indicate that this receptor may confer a growth advantage to these cells [35]. The high
affinity of FRα for 5-MTHF suggest that this GPI-anchored receptor may play an important
role in maintaining nuclear folates even at low extracellular concentrations of this vitamin.
This hypothesis is supported by the finding that induction of FRα expression in cells that
normally do not express this receptor allows the cells to grow in low nanomolar folate con‐
centrations [36]. On the other hand, the observation that methionine synthase was localized in
the nucleus of melanoma cells could explain many of the unanswered questions on the role
and regulation of the folate metabolism in the nucleus of these cancer cells. The methionine
synthase -mediated catalysis of 5-MTHF would first supply THF and methionine to maintain
both dTTP synthesis and the methylation reactions in the nucleus of the cells (Figure 1C)
and second would prevent the nuclear accumulation of 5-MTHF, a potent inhibitor of SHMT
[29]. Therefore, in melanoma, the existence of a specific folate transport pathway from the
plasma membrane to the nucleus, mediated by FRα, is possible [37] and could shed light on
the unknown function of overexpressed FRα in cancer cells [38].
4. Melanoma coordinates general and cell-specific mechanisms to promote
MTX resistance
4.1. MTX induces E2F1 demethylation and prevents dTTP depletion in melanoma
MTX acts as a cytostatic agent in melanoma cells [6]. To discriminate between the mechanisms
by which MTX could induce cell growth arrest without inducing apoptosis, the effect of this
drug on the cell cycle of several melanoma cell lines was analysed [7]. The results indicated
that, in all the tested melanoma cell lines, MTX conferred an arrest in early S phase; the G1 peak
shifted toward the G1/S border, and cells were arrested with a minimal increase in their DNA
content. Because S phase arrest has been recognized as a major mechanism of resistance in
response to non-toxic concentrations of drugs that induce DNA replication stress, these pre‐
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liminary results suggest that moderate DNA damage could be responsible for the cytostatic
effect of MTX on melanoma cells.
Figure 2. MTX enhances the transactivation potential of E2F1 in melanoma cells. (A) The time-dependent effect of
MTX treatment (1 µM) on the expression of E2F1, DHFR, and TS proteins as assayed by western blot (WB). (B) ChIP
experiments showing the occupancy of E2F1 and Rb on the DHFR promoter of B16/F10 melanoma cells (*P < 0.05). (C)
The upper panels represent the time-dependent effects of MTX (1 μM) treatment on the expression and phosphoryla‐
tion state of the Rb protein as assayed by WB. The lower panel depicts the Rb mRNA expression as assayed by qRT-
PCR. The changes observed after MTX treatment were not statistically significant. (D) Co-immunoprecipitation assays
were performed to test the interaction between Rb and E2F1.
To understand the mechanisms involved in G1 cell cycle progression in MTX-treated melano‐
ma cells, the effect of this drug on several G1 cell cycle components was analysed. Although
the protein levels of E2F1 were not affected by MTX (Figure 2A), this drug significantly in‐
creased the protein levels of DHFR and thymidylate synthase (TS), two E2F1-target genes
involved in folate metabolism and required for G1 progression and DNA synthesis (Figure
2A). Chromatin immunoprecipitation (ChIP) experiments that were designed to analyze the
occupancy of E2F1 on the DHFR promoter of B16/F10 melanoma cells indicated that MTX
stimulated the transcriptional activity of E2F1 (Figure 2B). First, we observed that MTX in‐
duced a transient decrease in the hypophosphorylated Rb protein in melanoma cells (Figure
2C) as evidenced by a noticeable lack of Rb co-immunoprecipitation with E2F1 in 10 h MTX-
treated SK-MEL-28 cells when compared to untreated controls (Figure 2D). In addition, mass
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peptide analysis of immunoprecipitated E2F1, after trypsin digestion (Figure 3), indicated that
MTX promoted the demethylation of E2F1 at Lys185 (Figures 3B and 3D). A negative crosstalk
between methylation and other posttranslational modifications of E2F1, such as acetylation
and phosphorylation, has been recently described [39]. We observed that MTX induced the
transient co-immunoprecipitation of E2F1 with p300/CBP-associated factor (P/CAF) (Figure
3B), an interaction that has been associated with the transcriptionally active hyperacetylated
form of this transcription factor [40]. The hyperacetylated status of E2F1 after MTX treatment
was also confirmed by MALDI-TOF mass spectrometry (Figures 3B and 3D). In response to
severe DNA damage, the E2F1 protein is stabilized through distinct mechanisms, including
direct phosphorylation by Chk2 at Ser364 [41] or ATM kinase at Ser31 [42]. As we did not observe
phosphorylation of E2F1 after MTX treatment (Figures 3C and 3D), these data further suggest
that MTX induced moderate DNA damage without inducing double strand breaks (DSBs) [43].
MTX increased E2F1 levels in sensitive cancer cells [16]. However, we did not observe an MTX-
mediated increase in E2F1 levels in melanoma cells (Figure 2A) [7], a result that could be
explained, at least in part, by the results obtained after determination of dNTP pools in mel‐
anoma cells (Figure 4). Contrary to the effects of MTX in most cancer cells [16], this drug
increased the levels of dTTP in melanoma. Increased levels of dTTP were accompanied by a
decrease in dCTP levels, which resulted in a nucleotide imbalance that favored thymidine
excess. The MTX-induced expression of DHFR and TS (Figure 2A) and the low levels of MTX
accumulated in melanoma cells [6] could explain this paradoxical response of melanoma cells
to a cytotoxic drug that typically depletes dTTP levels.
The data obtained in our study indicate that melanoma cells respond to the lack of folate
coenzymes by enhancing the transactivational potential of E2F1. We observed that treatment
of melanoma cells with MTX transiently affected the stability of Rb and the posttranslational
state of E2F1 [7]. A crosstalk between the methylated and acetylated forms of E2F1 has been
suggested [39]. Methylated E2F1 is prone to ubiquitination and degradation, whereas the de‐
methylation of E2F1 favors its P/CAF-dependent acetylation. Together, the results suggest a
model whereby the MTX-induced degradation of Rb and the demethylation of E2F1 would
result in the accumulation of E2F1 in its 'free' state, and in the absence of DNA damage, free
E2F1 would be acetylated, leading to the transcription of genes required for S phase (Figure
1C). The activation of E2F1 by MTX would allow S phase transition in melanoma cells, and
importantly for melanoma survival, cells would recover an operative folate cycle, thereby re‐
storing the original status of the Rb/E2F1 system. In the absence of exported MTX, high levels
of TS and DHFR would impede the lethal depletion of dTTP and in turn, would produce a
nucleotide imbalance that would favor a dTTP excess. Contrary to thymidine depletion, excess
thymidine stops cells in S phase by blocking synthesis of DNA, an effect known as ‘thymidine
block’ (Figure 1D) [15]. Recently, a mechanism by which dTTP allosterically feedback controls
E2F1 has been proposed [15,16]. According to this mechanism, excess of dTTP inhibits E2F1
accumulation acting either upon production of E2F1 or its degradation. Because control of
E2F1 is essential for cell survival, this mechanism would prevent E2F1 accumulation, which
would result in activation of apoptosis through a process that involves p53 or p73, cytochrome
c, and caspases (Figure 1D) [44].
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Figure 3. MTX induces demethylation and hyperacetylation of E2F1 in melanoma cells. (A) Schematic representation
of the E2F1 protein. Residues susceptible to methylation (K185), acetylation (K117, K120, and K125), and phosphory‐
lation (S31 and S364) are shown. (B) Relative intensity of unmethylated [(K)NHIQWLGSHTTVGVGGR(L); m/z
1820.0229] and hyperacetylated [(R)HPGKAcGVKAcSPGEKAcSR(Y); m/z 1589.8399] peptides in E2F1-trypsin digested
samples. Peptides were analyzed in untreated SK-MEL-28 cells (CN) or treated for 10 h with 1 μM MTX (*P < 0.05).
Intensities were normalized with respect to an internal matrix control. (C) Cell lysates from SK-MEL-28 cells that had
been treated with 1 μM MTX were used for IP assays with E2F1 to test the co-immunoprecipitation of E2F1 with
P/CAF and the phosphorylated state of E2F1. (D) MALDI-TOF mass spectra of tryptic digests of immunoprecipitated
E2F1. The characteristics peptides involving posttranslational modifications of E2F1 (methylation = Me, acetylation =
Ac, and phosphorylation = P), as well as their measured and theoretical m/z are shown.
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Figure 4. MTX does not deplete dTTP levels in melanoma cells. dNTP quantification in SK-MEL-28 control cells and
cells subjected to MTX (1 μM) treatment (*P < 0.05). Data collected from the left panel was used to determine the
total amounts of each dNTP at each time point. The percent contribution of each dNTP to the total pool after 24 h of
treatment is represented.
4.2. Excess of dTTP favours Chk1 activation in melanoma after MTX treatment
Excess thymidine induces little detectable DNA damage in the form of DSBs. The ATR-medi‐
ated response appears to play a more prominent role under these cellular conditions [45]. As
it is known that the central mechanism responsible for Chk1 activation upon DNA damage is
the distribution of ATR into nuclear foci [46], the effects of MTX on the localization of ATR
and the phosphorylation of Chk1 at Ser345 were analyzed by confocal microscopy and western
blot, respectively (Figures 5A and 5B). Time- and dose-dependent experiments clearly indi‐
cated that MTX induced Chk1 phosphorylation in melanoma cells. Because Chk1 phosphor‐
ylation may not directly correspond to Chk1 activation, we next analyzed the dose-dependent
effects of MTX on the stability of Cdc25A (Figure 5B). We found that Chk1 phosphorylation
led to a corresponding decrease in Cdc25A abundance, indicating that MTX not only conferred
Chk1 phosphorylation, but it also activated Chk1. Conversely, phosphorylation of Chk2 was
not observed in melanoma cells that had been treated with MTX for as long as 48 h (Figure
5B), indicating that this drug specifically induced Chk1 activation in response to DNA single
strand breaks (SSBs). To determine the extent to which Chk1 activation affected the resistance
of melanoma to MTX, we took two independent experimental approaches. First, we silenced
the expression of Chk1 in SK-MEL-28 (p53 mutant) cells and studied the sensitivity of the cells
to MTX (Figure 5C). The results indicated that the downregulation of Chk1 increased the sen‐
sitivity of SK-MEL-28 cells to MTX and led to apoptosis. As a second approach, we evaluated
the ability of Chk1 to protect B16/F10 murine cells (p53 wild-type) from MTX-induced apop‐
tosis by first inducing an S phase arrest with MTX and then treating the S-arrested cells with
a combination of MTX and 7-hydroxystaurosporine (UCN-01). We observed that B16/F10 S
phase-arrested cells were sensitive to MTX treatment after the effective inhibition of Chk1
(Figure 5C).
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Figure 5. MTX activates Chk1 in melanoma cells. (A) SK-MEL-28 cells were treated with 1 μM MTX for 24 h and then
examined for ATR nuclear foci. Nuclei were stained with DAPI. (B) The dose-dependent effects of MTX on Chk1 phos‐
phorylation and Cdc25A degradation in SK-MEL-28 after 24 h of drug exposure (*P < 0.05). MTX (1 μM) induced the
time-dependent phosphorylation of Chk1, but not Chk2, in different melanoma cell lines. (C) Chk1 siRNA sensitizes SK-
MEL-28 cells to MTX-induced toxicity (left panel). siControl (siCN)- and siChk1-transfected cells were treated with in‐
creasing doses of MTX for 48 h (*P < 0.05). The effective silencing of Chk1 was tested by WB. The induction of the
phosphorylated form of Chk1 was analyzed after 24 h of MTX treatment (1 μM). The induction of apoptosis by
UCN-01 in MTX-arrested B16/F10 cells is shown in the right-side panel. Cells were incubated with 1 μM MTX continu‐
ously for 32 h, and 50 nM UCN-01 was added at 24 h to one group of cells following splitting of the culture. As a
control experiment, SK-MEL-28 cells were treated with 50 nM UCN-01 only for 32 h.
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Inhibitors of DNA synthesis, such as excess thymidine, hydroxyurea, and camptothecin, are
normally poor inducers of apoptosis; however, these agents become potent inducers of death
in S phase cells upon the small interfering RNA-mediated depletion of Chk1 [45]. Here, we
observed that MTX activated Chk1 and induced an early S phase arrest in melanoma cells lines
that were harboring either wild-type or mutant p53. The impact of MTX on the survival of
Chk1-silenced melanoma cells and cells co-treated with UCN-01 indicates that MTX provokes
a ‘thymidine block’-like effect and that S phase arrest, as a result of Chk1 activation, might
constitute a major and general p53-independent mechanism that is responsible for the resist‐
ance of melanomas to MTX. However, it would be difficult to understand this extreme resist‐
ance without taking into account the melanosome-mediated exportation of MTX. The
activation of the DNA damage response pathway reflects the magnitude and extent of DNA
damage that occurs in response to a specific genotoxic agent, and a dual role of Chk1, de‐
pending on the extent of DNA damage, has been proposed [45]. Thus, Chk1 may play an anti-
apoptotic role in response to weaker replication fork stresses, whereas more catastrophic
damage, such as the accumulation of DNA strand breaks, may result in the activation of apop‐
tosis by Chk1. Together, the results indicate that low intracellular levels of MTX in melanoma
induce moderate DNA damage that favors the anti-apoptotic role of Chk1 (Figure 1D).
5. Therapeutical implications
Although melanoma resistance  to  MTX was  initially  thought  to  be  due  to  the  classical
mechanisms of resistance that have been observed in other epithelial cells, recent discov‐
eries  indicate  that  the  resistance  of  melanoma to  MTX might  be  due to  the  idiosyncra‐
sies  of  these  cancer  cells  [6,12]  where  drug  melanosomal  sequestration  and  its
subsequent cellular exportation may have a marked protagonist.  Unravelling the mecha‐
nisms of  melanoma resistance  to  MTX could,  therefore,  yield  important  information on
how  to  circumvent  this  resistance  and  could  have  important  pharmacological  implica‐
tions  for  the  design  of  novel  combined  therapies.  Taking  into  account  these  observa‐
tions,  uses  of  combined  treatments  with  MTX,  to  prevent  melanosomal  drug
sequestration [6,12] or to avoid MTX-induced S phase arrest [19], are rational therapeuti‐
cal approaches. The observation that MTX induces cellular depletion of DHF in melano‐
ma  [7]  could  generate  novel  combined  therapies  to  efficiently  inhibit  DHFR  with
antifolates transported into the cells  by FRα-independent processes.  Also,  of  great  inter‐
est  is  the  observed  effect  of  MTX on  the  posttranslational  status  of  E2F1  in  melanoma
(Figure  3).  Various  studies  have  suggested  that  E2F1  plays  dual  roles  in  cell  survival/
apoptosis  [47-50].  Therefore,  the  MTX-induced  demethylation  and  acetylation  of  E2F1
could favour melanoma cell  death when combined with E2F1-stabilizing drugs. In addi‐
tion to E2F1 phosphorylation,  acetylation has also been recognized to play a role in the
activation and stabilization of the E2F1 protein during DNA damage and apoptosis [40].
A possible  strategy to  favour E2F1 apoptosis  in  melanoma by the  combination of  MTX
with E2F1-stabilizing drugs is depicted in Figure 6.
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Figure 6. Proposed mechanism for the regulation of E2F1 by MTX. E2F1 is regulated by its interaction with Rb and by
several posttranslational modifications, including methylation (Me), acetylation (Ac) and phosphorylation (P) [39]. The
effects of MTX (red dashed line) on E2F1 status and that result in melanoma resistance are shown. A possible strategy
to stabilize E2F1 (green dashed lines) to induce apoptosis in melanoma cells is also displayed.
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6. Conclusions
Melanoma, the most aggressive form of skin cancer, is notoriously resistant to all current mo‐
dalities of cancer therapy, including to the drug MTX. Melanosomal sequestration and cellular
exportation of methotrexate have been proposed to be important melanoma-specific mecha‐
nisms that contribute to the resistance of melanoma to methotrexate. In addition, other mecha‐
nisms of  resistance  that  are  present  in  most  epithelial  cancer  cells  are  also  operative  in
melanoma. This chapter reviews how melanoma orchestrates these mechanisms to become ex‐
tremely resistant to methotrexate, where both E2F1 and Chk1, two molecules with dual roles in
survival/apoptosis, play prominent roles. The results indicated that MTX induced the depletion
of DHF in melanoma cells, which stimulated the transcriptional activity of E2F1. The elevate ex‐
pression of DHFR and TS, two E2F1-target genes involved in folate metabolism and required
for G1 progression, favoured dTTP accumulation, which promoted DNA single strand breaks
and the subsequent activation of Chk1. Under these conditions, melanoma cells are protected
from apoptosis by arresting their cell cycle in S phase. Excess of dTTP could also inhibit E2F1-
mediated apoptosis in melanoma cells. In addition, these discoveries could open the way for the
development of new combined and directed therapies against this elusive skin pathology.
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